GB1466932A - Creación de Inventos y Patentes con Inteligencia Artificial

GB1466932A – 11-h-pyrimido-4,5-b- 1,4,-benzodiazepines
– Google Patents

GB1466932A – 11-h-pyrimido-4,5-b- 1,4,-benzodiazepines
– Google Patents
11-h-pyrimido-4,5-b- 1,4,-benzodiazepines

Info

Publication number
GB1466932A

GB1466932A
GB1651074A
GB1651074A
GB1466932A
GB 1466932 A
GB1466932 A
GB 1466932A
GB 1651074 A
GB1651074 A
GB 1651074A
GB 1651074 A
GB1651074 A
GB 1651074A
GB 1466932 A
GB1466932 A
GB 1466932A
Authority
GB
United Kingdom
Prior art keywords
alkyl
amino
ethoxy
pyrimidobenzodiazepines
aminobenzylamino
Prior art date
1973-04-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired

Application number
GB1651074A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bristol Myers Co

Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1973-04-16
Filing date
1974-04-16
Publication date
1977-03-09

1973-04-16
Priority claimed from US351217A
external-priority
patent/US3872122A/en

1974-04-16
Application filed by Bristol Myers Co
filed
Critical
Bristol Myers Co

1977-03-09
Publication of GB1466932A
publication
Critical
patent/GB1466932A/en

Status
Expired
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07D—HETEROCYCLIC COMPOUNDS

C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings

C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members

C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms

C07D239/32—One oxygen, sulfur or nitrogen atom

C07D239/42—One nitrogen atom

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07D—HETEROCYCLIC COMPOUNDS

C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings

C07D239/46—Two or more oxygen, sulphur or nitrogen atoms

C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07D—HETEROCYCLIC COMPOUNDS

C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings

C07D239/46—Two or more oxygen, sulphur or nitrogen atoms

C07D239/48—Two nitrogen atoms

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07D—HETEROCYCLIC COMPOUNDS

C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms

C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines

C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems

C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring

C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4

C07D265/26—Two oxygen atoms, e.g. isatoic anhydride

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07D—HETEROCYCLIC COMPOUNDS

C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 – C07D477/00

C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 – C07D477/00 in which the condensed system contains two hetero rings

C07D487/04—Ortho-condensed systems

Abstract

1466932 Pyrimidobenzodiazepines BRISTOL-MYERS CO 16 April 1974 [16 April 1973 25 Feb 1974] 16510/74 Heading C2C Pyrimidobenzodiazepines are prepared by the following routes (R,R3=H, C 1-6 alkyl, R5Ph(CH 2 ) n ; n=1-4; R5=H, F, Cl, Br, CF 3 , C 1-6 alkyl or alkoxy; R2,4=H, F, Cl, Br, CF 3 , NO 2 , C 1-6 alkyl or alkoxy; X=halogen; Y=di(C 1-6 alkyl)amino, C 3-6 cycloalkylamino, benzylamino, phenethylamino, di(C 1-6 alkyl)amino(C 1-6 alkyl)amino), optionally followed by salt formation. The 5,6- dihydro – 11H – pyrimido[4,5-b][1,4]benzodiazepines may alternatively be prepared by cyclizing a 5-(o-aminobenzylamino)-4-alkoxypyrimidine with a strong base in the presence of a solvent, optionally followed by introduction of an 11-substituent. The preparation of benzyl 4-ethoxy-5-pyrimidylcarbamate, 5 – amino – 4 – ethoxypyrimidine, 4 – ethoxy – 5 – (o – nitrobenzalamino)pyrimidine, 4 – ethoxy – 5 – (o – nitrobenzylamino)pyrimidine, 5 – (o – aminobenzylamino) – 4 – ethoxypyrimidine, N,5 – dimethylisatoic anhydride and methyl N,5-dimethylanthranilate is described. The above compounds possess antihypoxic, hypothermic, antipyretic and anti-inflammatory activity, and may be administered in the form of pharmaceutical preparations containing them in association with a carrier.

GB1651074A
1973-04-16
1974-04-16
11-h-pyrimido-4,5-b- 1,4,-benzodiazepines

Expired

GB1466932A
(en)

Applications Claiming Priority (2)

Application Number
Priority Date
Filing Date
Title

US351217A

US3872122A
(en)

1973-04-16
1973-04-16
11 H-Pyrimido{8 4,5-b{9 {8 1,4{9 benzodiazepines

US445382A

US3880855A
(en)

1973-04-16
1974-02-25
5,6-DIHYDRO-11-H-pyrimido{8 4,5-b{9 {8 1,4{9 benzodiazepines

Publications (1)

Publication Number
Publication Date

GB1466932A
true

GB1466932A
(en)

1977-03-09

Family
ID=26996992
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

GB1651074A
Expired

GB1466932A
(en)

1973-04-16
1974-04-16
11-h-pyrimido-4,5-b- 1,4,-benzodiazepines

Country Status (7)

Country
Link

US
(1)

US3880855A
(en)

JP
(1)

JPS5035192A
(en)

CA
(1)

CA1034125A
(en)

DE
(1)

DE2418285A1
(en)

FR
(1)

FR2225158B1
(en)

GB
(1)

GB1466932A
(en)

NL
(1)

NL7405012A
(en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US5550124A
(en)

1991-12-10
1996-08-27
University Of Southern California
Use of peripheral-type benzodiazpine sites for treatment of CNS trauma or disease

DE102005061655A1
(en)

2005-12-22
2007-06-28
Merck Patent Gmbh
New fused-ring diazepinone compounds, useful for treatment and prevention of e.g. cancers and arteriosclerosis, are inhibitors of serine-threonine kinase

ES2351367T3
(en)

2006-02-14
2011-02-03
Vertex Pharmaceuticals Incorporated

USEFUL DIHYDRODIAZEPINS AS INHIBITORS OF PROTEIN KINASES.

JP5243970B2
(en)

2006-02-14
2013-07-24
バーテックスファーマシューティカルズインコーポレイテッド

Dihydrodiazepines useful as inhibitors of protein kinases

KR20120096474A
(en)

2009-09-25
2012-08-30
버텍스 파마슈티칼스 인코포레이티드
Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors

MX2012003484A
(en)

2009-09-25
2012-04-20
Vertex Pharma
Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors.

CN103012397B
(en)

2011-09-26
2017-03-01
赛诺菲
Pyrazolo (E)-3-(3-Acetyl-4-hydroxy-5-methoxy-phenyl)-N-(4-hydroxy-1-methyl-3-octyloxy-2-oxo-1,2-dihydro-quinolin-7-yl)-acrylamide, its preparation method and its therapeutic use

US9169246B2
(en)

2011-09-26
2015-10-27
Sanofi
Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof

PT2573073E
(en)

2011-09-26
2015-02-05
Sanofi Sa
Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof

1974

1974-02-25
US
US445382A
patent/US3880855A/en
not_active
Expired – Lifetime

1974-04-09
FR
FR7412385A
patent/FR2225158B1/fr
not_active
Expired

1974-04-11
CA
CA197,462A
patent/CA1034125A/en
not_active
Expired

1974-04-11
NL
NL7405012A
patent/NL7405012A/xx
not_active
Application Discontinuation

1974-04-16
GB
GB1651074A
patent/GB1466932A/en
not_active
Expired

1974-04-16
DE
DE2418285A
patent/DE2418285A1/en
not_active
Withdrawn

1974-04-16
JP
JP49041835A
patent/JPS5035192A/ja
active
Pending

Also Published As

Publication number
Publication date

JPS5035192A
(en)

1975-04-03

FR2225158B1
(en)

1978-07-21

AU6731274A
(en)

1975-10-02

CA1034125A
(en)

1978-07-04

NL7405012A
(en)

1974-10-18

DE2418285A1
(en)

1974-11-07

US3880855A
(en)

1975-04-29

FR2225158A1
(en)

1974-11-08

Información de contacto